NCT03087591View on ClinicalTrials.gov

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

December 8, 2020

Conditions
Metastatic Malignant Neoplasm in the BrainMetastatic Solid NeoplasmRecurrent Colorectal CarcinomaRecurrent Pancreatic CarcinomaRecurrent Solid NeoplasmStage IV Colorectal CancerStage IV Pancreatic CancerStage IVA Colorectal CancerStage IVA Pancreatic CancerStage IVB Colorectal CancerStage IVB Pancreatic CancerUnresectable Solid Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401

Given IV

Trial Locations (1)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03087591 - APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter